Spectral Medical (PK) Stock Price - EDTXF

0.4675
0.0275 (6.25%)
0.4675
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Small Cap Pro
Monthly Subscription
for only
$49.05
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
VAT not included
Company Name Stock Ticker Symbol Market Type
Spectral Medical Inc (PK) EDTXF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.0275 6.25% 0.4675 0.44 0.47645 0.44 0.44 11:40:29
Bid Price Ask Price Spread Spread % News
0.4791 0.49 0.011 2.24% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
19 45,840 $ 0.466209 $ 21,371 25,898 0.259774 - 1.00
Last Trade Time Type Quantity Stock Price Currency
11:04:30 4,410 $ 0.4675 USD

Spectral Medical (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 106.64M 228.11M - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
62.30k $ - 0.00% - -

more financials information »

Spectral Medical (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EDTXF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.43050.476450.420420.438276322,5100.0378.59%
1 Month0.5180450.53340.420420.468183125,558-0.05055-9.76%
3 Months0.2597740.580.2597740.439921131,4110.2077379.96%
6 Months0.497940.650.2597740.49002528,302-0.03044-6.11%
1 Year0.2811.000.2597740.45470723,2640.186566.37%
3 Years0.37471.000.1629850.344682720,2410.092824.77%
5 Years0.74351.49940.1350.433972534,952-0.276-37.12%

Spectral Medical (PK) Description

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA), the only FDA-cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.


Your Recent History
USOTC
EDTXF
Spectral M..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.